0001104659-25-069564.txt : 20250722 0001104659-25-069564.hdr.sgml : 20250722 20250722144651 ACCESSION NUMBER: 0001104659-25-069564 CONFORMED SUBMISSION TYPE: D PUBLIC DOCUMENT COUNT: 1 ITEM INFORMATION: Rule 506(b) provides a "safer harbor" for a private offering FILED AS OF DATE: 20250722 DATE AS OF CHANGE: 20250722 EFFECTIVENESS DATE: 20250722 FILER: COMPANY DATA: COMPANY CONFORMED NAME: HYPERION DEFI, INC. CENTRAL INDEX KEY: 0001682639 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences EIN: 471178401 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: D SEC ACT: 1933 Act SEC FILE NUMBER: 021-552478 FILM NUMBER: 251139968 BUSINESS ADDRESS: STREET 1: 23461 SOUTH POINTE DRIVE, STREET 2: SUITE 390 CITY: LAGUNA HILLS STATE: CA ZIP: 92653 BUSINESS PHONE: 833-393-6684 MAIL ADDRESS: STREET 1: 23461 SOUTH POINTE DRIVE, STREET 2: SUITE 390 CITY: LAGUNA HILLS STATE: CA ZIP: 92653 FORMER COMPANY: FORMER CONFORMED NAME: EYENOVIA, INC. DATE OF NAME CHANGE: 20160818 D 1 primary_doc.xml X0708 D LIVE 0001682639 HYPERION DEFI, INC. 23461 SOUTH POINTE DRIVE, SUITE 390 LAGUNA HILLS CA CALIFORNIA 92653 833-393-6684 DELAWARE Eyenovia, Inc. EYENOVIA, INC. Corporation true Michael Rowe 23461 South Pointe Drive, Suite 390 Laguna Hills CA CALIFORNIA 92653 Executive Officer Director Hyunsu Jung 23461 South Pointe Drive, Suite 390 Laguna Hills CA CALIFORNIA 92653 Executive Officer Director Michael Geltzeiler 23461 South Pointe Drive, Suite 390 Laguna Hills CA CALIFORNIA 92653 Director Rachel Jacobson 23461 South Pointe Drive, Suite 390 Laguna Hills CA CALIFORNIA 92653 Director Ellen Strahlman 23461 South Pointe Drive, Suite 390 Laguna Hills CA CALIFORNIA 92653 Director Pharmaceuticals Decline to Disclose 06b false 2025-06-20 false true true false 0 Chardan Capital Markets, LLC 000120128 None None One Pennslyvania Plaza, Suite 4800 New York NY NEW YORK 10119 All States false 49999999 49999999 0 false 5 3000000 true 0 Represents 6% of the transaction's gross proceeds issued as 307,692 shares of preferred stock to purchase 923,076 shares of common stock and warrants to purchase 1,846,153 shares of common stock. The conversion and exercise price are both $3.25 per share. 0 false HYPERION DEFI, INC. /s/ Michael Rowe Michael Rowe Chief Executive Officer and Director 2025-07-22